MINIMALLY INVASIVE SURGICAL MANAGEMENT FOR BENIGN PROSTATIC HYPERPLASIA: CURRENT EVIDENCE, CLINICAL OUTCOMES, AND FUTURE DIRECTIONS

Authors

  • Dr Khadka Ravi Roshan MBBS, MS Associate Professor ,Faculty of International Students, Asia International University Author

Keywords:

Benign prostatic hyperplasia, minimally invasive surgery, lower urinary tract symptoms, aquablation, Rezūm, prostatic urethral lift.

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common urological conditions affecting aging men and a major cause of lower urinary tract symptoms (LUTS). Although transurethral resection of the prostate (TURP) has long been regarded as the gold standard surgical treatment, the last two decades have witnessed significant advances in minimally invasive surgical therapies (MISTs). These techniques aim to provide effective symptom relief while minimizing perioperative morbidity, preserving sexual function, and reducing hospitalization. Emerging procedures such as prostatic urethral lift (PUL), water vapor thermal therapy (Rezūm), prostatic artery embolization (PAE), aquablation, temporary implantable nitinol device (iTind), and laser-based enucleation techniques have expanded treatment options for patients with varying prostate sizes and comorbidities. This review summarizes the current evidence regarding minimally invasive surgical management of BPH, compares clinical outcomes and complications among available modalities, and discusses future directions including personalized treatment selection, technological innovation, and artificial intelligence-assisted surgical planning. MISTs have demonstrated promising efficacy and safety profiles, although long-term comparative data remain limited for several newer technologies.

References

1.Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-479.

2.McVary KT. BPH: Epidemiology and comorbidities. Am J Manag Care. 2006;12.

3.Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on BPH. Eur Urol. 2015;67(6):1099-1109.

4.Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of TURP. Eur Urol. 2008;54(5):969-980.

5.Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of LUTS attributed to BPH: AUA Guideline. J Urol. 2019;202(3):592-598.

6.Roehrborn CG. Prostatic urethral lift: Clinical evidence and outcomes. Can J Urol. 2017;24(3):8802-8813.

7.Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Five-year results of the L.I.F.T. study. Can J Urol. 2017;24(3):8802-8813.

8.McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor therapy for BPH. J Urol. 2019;201(4):731-742.

9.McVary KT, Rogers T, Roehrborn CG. Final 5-year outcomes of Rezūm therapy. Urology. 2021;148:256-262.

10.Carnevale FC, Iscaife A. Prostatic artery embolization for BPH. Radiology. 2020;295(2):289-301.

11.Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, et al. PAE versus TURP for BPH. Lancet. 2018;391(10131):1929-1938.

12.Gilling P, Anderson P, Tan A, Barber N, Bidair M, Bolton D, et al. Aquablation for BPH. J Urol. 2018;199(5):1252-1261.

13.Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Five-year outcomes of aquablation. J Urol. 2022;207(4):800-806.

14.Elmansy HM, Krambeck AE, Holmium laser enucleation of the prostate. Eur Urol. 2012;62(5):865-871.

15.Bachmann A, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, et al. 180-W XPS GreenLight laser vaporization outcomes. Eur Urol. 2014;65(5):931-942.

Downloads

Published

2026-06-09